Comparative effectiveness research: Policy context, methods development and research infrastructure
- PMID: 20564311
- DOI: 10.1002/sim.3818
Comparative effectiveness research: Policy context, methods development and research infrastructure
Abstract
Comparative effectiveness research (CER) has received substantial attention as a potential approach for improving health outcomes while lowering costs of care, and for improving the relevance and quality of clinical and health services research. The Institute of Medicine defines CER as 'the conduct and synthesis of systematic research comparing different interventions and strategies to prevent, diagnose, treat, and monitor health conditions. The purpose of this research is to inform patients, providers, and decision-makers, responding to their expressed needs, about which interventions are most effective for which patients under specific circumstances.' Improving the methods and infrastructure for CER will require sustained attention to the following issues: (1) Meaningful involvement of patients, consumers, clinicians, payers, and policymakers in key phases of CER study design and implementation; (2) Development of methodological 'best practices' for the design of CER studies that reflect decision-maker needs and balance internal validity with relevance, feasibility and timeliness; and (3) Improvements in research infrastructure to enhance the validity and efficiency with which CER studies are implemented. The approach to addressing each of these issues should be informed by the understanding that the primary purpose of CER is to help health care decision makers make informed clinical and health policy decisions.
Copyright (c) 2010 John Wiley & Sons, Ltd.
Comment in
-
The promise and realities of comparative effectiveness research.Stat Med. 2010 Aug 30;29(19):1977-81; discussion 1996-7. doi: 10.1002/sim.3936. Stat Med. 2010. PMID: 20683886 Free PMC article.
-
The historical and moral imperatives of comparative effectiveness research.Stat Med. 2010 Aug 30;29(19):1982-4; discussion 1996-7. doi: 10.1002/sim.3927. Stat Med. 2010. PMID: 20683887 No abstract available.
-
What is evidence?Stat Med. 2010 Aug 30;29(19):1985-8; discussion 1996-7. doi: 10.1002/sim.3933. Stat Med. 2010. PMID: 20683888 Free PMC article.
-
Comments on 'Comparative effectiveness research: Policy context, methods development and research infrastructure'.Stat Med. 2010 Aug 30;29(19):1989-90; discussion 1996-7. doi: 10.1002/sim.3926. Stat Med. 2010. PMID: 20683889 No abstract available.
-
On the limitations of comparative effectiveness research.Stat Med. 2010 Aug 30;29(19):1991-5; discussion 1996-7. doi: 10.1002/sim.3960. Stat Med. 2010. PMID: 20683890 No abstract available.
Similar articles
-
Facts, fallacies, and politics of comparative effectiveness research: Part I. Basic considerations.Pain Physician. 2010 Jan-Feb;13(1):E23-54. Pain Physician. 2010. PMID: 20119474 Review.
-
Facts, fallacies, and politics of comparative effectiveness research: Part 2 - implications for interventional pain management.Pain Physician. 2010 Jan-Feb;13(1):E55-79. Pain Physician. 2010. PMID: 20119475 Review.
-
The impact of comparative effectiveness research on interventional pain management: evolution from Medicare Modernization Act to Patient Protection and Affordable Care Act and the Patient-Centered Outcomes Research Institute.Pain Physician. 2011 May-Jun;14(3):E249-82. Pain Physician. 2011. PMID: 21587337 Review.
-
Defining comparative effectiveness research: the importance of getting it right.Med Care. 2010 Jun;48(6 Suppl):S7-8. doi: 10.1097/MLR.0b013e3181da3709. Med Care. 2010. PMID: 20473202
-
The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.Value Health. 2009 Nov-Dec;12(8):1086-99. doi: 10.1111/j.1524-4733.2009.00605.x. Epub 2009 Sep 10. Value Health. 2009. PMID: 19744291
Cited by
-
Comparative effectiveness research in the "real" world: lessons learned in a study of treatment-resistant hypertension.J Am Soc Hypertens. 2013 Jan-Feb;7(1):95-101. doi: 10.1016/j.jash.2012.12.002. J Am Soc Hypertens. 2013. PMID: 23321408 Free PMC article. Review.
-
Innovative Clinical Trial Designs: Toward a 21st-Century Health Care System.Stat Biosci. 2011 Dec;3(2):145-168. doi: 10.1007/s12561-011-9042-5. Stat Biosci. 2011. PMID: 26140056 Free PMC article.
-
Added value of cost-utility analysis in simple diagnostic studies of accuracy: (18)F-fluoromethylcholine PET/CT in prostate cancer staging.Am J Nucl Med Mol Imaging. 2015 Jan 15;5(2):183-94. eCollection 2015. Am J Nucl Med Mol Imaging. 2015. PMID: 25973339 Free PMC article.
-
Are the effects of homeopathy attributable to a statistical artefact? A reanalysis of an observational study.Evid Based Complement Alternat Med. 2013;2013:612890. doi: 10.1155/2013/612890. Epub 2013 Dec 15. Evid Based Complement Alternat Med. 2013. PMID: 24396390 Free PMC article.
-
Evaluating treatment effectiveness under model misspecification: A comparison of targeted maximum likelihood estimation with bias-corrected matching.Stat Methods Med Res. 2016 Oct;25(5):2315-2336. doi: 10.1177/0962280214521341. Epub 2014 Feb 12. Stat Methods Med Res. 2016. PMID: 24525488 Free PMC article.